Company / R&D Expense
PLIANT THERAPEUTICS, INC. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$169.3M
FY2025
5-year range
$47.4M / $169.3M
FY2021-FY2025
Trend
+74.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $78M to $169M over the past 2 years.
Based on SEC 10-K filings.
$169M in FY2025 with a 5-year CAGR of +29.0%.
Improved from $78M to $169M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +29.7%
- 5-Year CAGR
- +29.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +29.0%, indicating consistent growth.
- In FY2025, r&d expense increased 74.7% year-over-year.
- Lowest r&d expense in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -4.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $169.3M | +74.7% |
| FY2024 | $96.9M | +25.0% |
| FY2023 | $77.5M | +0.0% |
| FY2022 | $77.5M | +63.8% |
| FY2021 | $47.4M | +0.0% |
| FY2020 | $47.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026